Skip to content

Based on the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model with ID 6438950a00000074, titled "Human metapneumovirus M2-2 inhibition of RIGI-MAVS signaling (Human-Metapneumovirus)".

Review of GO-CAM model: gomodel:6438950a00000074

Summary of the Model

This GO-CAM model represents how Human metapneumovirus (HMPV) M2-2 protein inhibits the RIG-I-MAVS signaling pathway, which is part of the host innate immune response to viral infection. The model depicts:

  1. The normal RIG-I-mediated pattern recognition receptor signaling pathway
  2. How the viral protein M2-2 negatively regulates this pathway
  3. Key interactions between host proteins (RIG-I, MAVS, TRIM25) and viral factors (M2-2)

Evaluation of the Biological Content

The model correctly represents the current understanding of how HMPV M2-2 inhibits the RIG-I-MAVS signaling pathway based on the referenced literature:

  • The central mechanism shown in the model reflects recent findings that HMPV M2-2 prevents TRIM25-mediated ubiquitination of RIG-I, as demonstrated in the 2022 paper by Tanaka et al. (PMID:36045682)
  • The representation aligns with the earlier finding that M2-2 targets MAVS to inhibit innate cellular signaling (PMID:23015697)

Technical Assessment of Model Structure

The model includes the following molecular activities:

  1. RIG-I (UniProtKB:O95786) with pattern recognition receptor activity (GO:0038187)
  2. TRIM25 (UniProtKB:Q14258) with ubiquitin protein ligase activity (GO:0061630)
  3. MAVS (UniProtKB:Q7Z434) with signaling adaptor activity (GO:0035591)
  4. TRAF6 (UniProtKB:Q9Y4K3) with ubiquitin protein ligase activity (GO:0061630)
  5. Human metapneumovirus M2-2 protein (UniProtKB:Q6WB96) with protein sequestering activity (GO:0140311)

The causal relationships are represented through the following connections:

  • RIG-I provides input for TRIM25 (RO:0002413)
  • TRIM25 directly positively regulates MAVS (RO:0002629)
  • M2-2 directly negatively regulates TRIM25 and MAVS (RO:0002630)

Strengths of the Model

  1. Biological accuracy: The model accurately represents the current understanding of how HMPV M2-2 interferes with RIG-I-MAVS signaling.
  2. Evidence support: Activities are properly supported by evidence codes and PMID references.
  3. Cellular components: All proteins are correctly located in their cellular compartments (cytoplasm for most proteins, host cell cytoplasm for viral M2-2).
  4. Biological process context: All activities are correctly placed within the "cytoplasmic pattern recognition receptor signaling pathway" (GO:0002753).

Areas for Improvement

  1. Complex representation: The model doesn't explicitly show the RIG-I/TRIM25 complex formation that is described in the literature. According to the "How to annotate complexes in GO-CAM" guidelines, if the activity is shared by several proteins or if the specific subunit carrying the activity is known, the complex should be represented accordingly.

  2. Ubiquitination details: The model doesn't explicitly capture that TRIM25 ubiquitinates RIG-I with K63-linked polyubiquitin chains, which is a key mechanism inhibited by M2-2. This could be better represented by including the specific ubiquitination target.

  3. RIG-I activation cycle: The model could be enhanced by showing the conformational change of RIG-I upon RNA binding that exposes the CARD domains for interaction with TRIM25.

  4. Additional interactions: The model could include other interactions described in the literature:

  5. The direct binding of M2-2 to the SPRY domain of TRIM25
  6. The role of TRAF3 in the pathway (currently only TRAF6 is shown)
  7. The downstream effects on IRF3/7 activation and IFN production

Recommendations for Improvement

  1. Add RIG-I/TRIM25 complex: Consider representing the complex formation between RIG-I and TRIM25 since this is a key target for M2-2 inhibition.

  2. Expand ubiquitination details: Specify that TRIM25 catalyzes K63-linked ubiquitination of RIG-I at specific lysine residues (especially K172) as described in the literature.

  3. Include conformational changes: Consider adding the RNA-induced conformational change of RIG-I that exposes the CARD domains for TRIM25 interaction.

  4. Add downstream signaling: Extend the model to include downstream effects on IRF3/7 activation and type I interferon production.

  5. Include additional viral strategies: Consider expanding the model to show comparisons with how other viruses target the same pathway (e.g., HRSV NS1), which would make it more comprehensive.

Conclusion

The GO-CAM model gomodel:6438950a00000074 is a scientifically accurate representation of how HMPV M2-2 inhibits RIG-I-MAVS signaling, with proper evidential support. It correctly captures the key molecular activities, their cellular locations, and the causal relationships between them. The model effectively represents the current understanding of this viral immune evasion mechanism, though it could be enhanced by incorporating more details about complex formation, specific ubiquitination events, and downstream signaling effects.

The model follows GO-CAM best practices in terms of causal relations and evidence attribution, making it a valuable resource for understanding HMPV immune evasion strategies. With the suggested improvements, it could serve as an even more comprehensive reference for researchers interested in viral manipulation of innate immune signaling.